Eli Lilly’s (NYSE: LLY) market isn’t out of the weeds yet but will rebound strongly in 2025. The Q3 results failed to spark a ...

WNBA legend and all-time scoring leader Diana Taurasi shows she' passionate about off-court causes involving health and wellbeing.

Baron Funds, an investment management company, released its “Baron Health Care Fund” third quarter 2024 investor letter. A ...

Despite disappointing third-quarter results for Regeneron’s high-dose Eylea injection, analysts continued to be cautiously ...

Sanofi (SNY) has released an update. Sanofi’s Dupixent has shown promising results in a Phase 3 trial for treating chronic spontaneous ...

Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report third-quarter results on Oct. 31, 2024. The Zacks ...

Over the last 25 years, UConn great Diana Taurasi has been a star on the basketball court while living with the skin condition eczema.

The pharmaceutical company reported third-quarter earnings and sales that beat analysts’ expectations, boosted by ...

Sanofi attributed its double-digit growth to growth in vaccines, particularly its latest flu jab. Another major revenue contributor was Dupixent, the company's COPD treatment, whose sales surged 24% ...

Eli Lilly's Ebglyss improves skin and itch symptoms in eczema patients, including Dupixent-treated cases, with positive Phase ...

Key drugs from Johnson & Johnson and Eli Lilly stand to bolster their respective cases in competitive dermatology markets ...

Eli Lilly (LLY) said a study of its drug Ebglyss showed it was able to improve skin and itch in patients with atopic ...